Clinical Trials Browser

Advanced Solid Tumors

NCT05379595 2026-04-13

OrigAMI-1

Phase 1/2 Recruiting

225 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT06469944 2026-04-13

MK-3475-06C

Phase 1/2 Recruiting

160 enrolled

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT05919264 2026-04-09

FOG-001 in Locally Advanced or Metastatic Solid Tumors

Phase 1/2 Recruiting

595 enrolled

CNSGastrointestinalGenitourinaryGynecologicSarcoma

Craniopharyngioma, Carcinoma, Hepatocellular, Neoplasm Metastasis, Neoplasms, Adenomatous Polyposis Coli, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Desmoid Tumors

NCT06483555 2026-04-01

PANGEA

Phase 1/2 Recruiting

104 enrolled

DermatologicGastrointestinal

Pancreatic Neoplasms, Neoplasms, Basal Cell

NCT06780111 2026-03-31

MK-3475-06E

Phase 1/2 Recruiting

298 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT07214298 2026-02-06

Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma

Phase 1/2 Recruiting

35 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT04421820 2026-01-27

BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours

Phase 1/2 Recruiting

220 enrolled

Gastrointestinal

Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT06428409 2026-01-22

MK-9999-02A

Phase 1/2 Recruiting

220 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Colorectal Neoplasms

NCT07056777 2026-01-13

Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer

Phase 1/2 Recruiting

186 enrolled

Gastrointestinal

Gastrointestinal Neoplasms

NCT04689347 2026-01-12

5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.

Phase 1/2 Recruiting

27 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT06385925 2025-12-15

A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Phase 1/2 Recruiting

440 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT06703177 2025-12-03

A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors

Phase 1/2 Recruiting

876 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT05482893 2025-11-04

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

Phase 1/2 Recruiting

258 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT07204574 2025-10-02

The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer

Phase 1/2 Recruiting

40 enrolled

CRC

NCT06741020 2025-05-23

HAICI

Phase 1/2 Recruiting

10 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT06139211 2024-12-20

A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors

Phase 1/2 Recruiting

186 enrolled

Other solid neoplasm

Advanced Solid Tumor

Clinical Trials

A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors

OrigAMI-1

MK-3475-06C

FOG-001 in Locally Advanced or Metastatic Solid Tumors

PANGEA

MK-3475-06E

Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma

BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours

MK-9999-02A

Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer

5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.

A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer

HAICI

A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors